drugset / Trial / NCT05630768
Efficacy and Safety of Actonel® After Denosumab Discontinuation in Postmenopausal Osteoporosis Women
NaSingle-groupOpen-labelPrevention
Summary
To evaluate the effect of 1 year of risedronate treatment on the prevention of bone loss after denosumab discontinuation in denosumab-treated post-menopausal osteoporosis for a year
Timeline
- Start
- 2023-01-03
- Primary completion
- 2025-07-23
- Completion
- 2025-07-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Risedronate | Small molecule | 35 mg | Oral |
| Background | Calcium carbonate | Other / unclassified | — | Oral |
| Background | Vitamin D | Other / unclassified | — | Oral |